{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"The Drugs.com Monthly Update Podcast","title":"Drugs.com - Monthly Update November 2025","html":"","width":"100%","height":180,"duration":266,"description":"In this episode, we explore key FDA approvals from November 2025, including treatments like Keytruda Qlex for bladder cancer, Epkinly for follicular lymphoma, and the long-acting Eylea HD for macular edema. Discover what these developments mean for patients and professionals alike.Keytruda (pembrolizumab), approved in combination with Padcev as neoadjuvant treatment for adults with muscle-invasive bladder cancer ineligible for cisplatin-containing chemotherapy, demonstrating a 60% reduction in event-free survival events.Epkinly (epcoritamab-bysp) plus rituximab and lenalidomide, approved for adults with relapsed or refractory follicular lymphoma, showing a 79% reduction in disease progression risk through T-cell engagement with malignant B-cells.Darzalex Faspro (daratumumab and hyaluronidase-fihj), now the first and only approved treatment for patients with high-risk smoldering multiple myeloma, significantly slowing disease progression.Eylea HD (aflibercept ophthalmic), approved for macular edema following retinal vein occlusion with extended up to every 8-week dosing after initial treatment, maintaining visual acuity with less frequent administration.Caplyta (lumateperone), newly approved as an add-on therapy for adults with major depressive disorder, enhancing outcomes when used alongside existing antidepressants.Chapters:Follow Drugs.com:X, Facebook, YoutubeSignup to our newslettersDownload the app","thumbnail_url":"https://img.transistorcdn.com/DIoKA3oI7NY0UzZ45F0V0NkzM-ycfQHBYCciiz9juOc/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9mMDAz/YzA5MzEzMjc1MDA5/YjRmMjFmMDA1MjYy/YmZmZC5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}